Trends in Brazilian market of antidepressants: A five-year dataset analysis
Introduction: Depression is an emotional disorder associated with morbidities and disabilities worldwide. The growing use of antidepressants is a concern for health managers because there are still unanswered questions on the effectiveness and safety of these medicines. Drug sales have increased in...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.893891/full |
| _version_ | 1811181360028581888 |
|---|---|
| author | Rogério Hoefler Rogério Hoefler Taís Freire Galvão Inês Ribeiro-Vaz Inês Ribeiro-Vaz Marcus Tolentino Silva |
| author_facet | Rogério Hoefler Rogério Hoefler Taís Freire Galvão Inês Ribeiro-Vaz Inês Ribeiro-Vaz Marcus Tolentino Silva |
| author_sort | Rogério Hoefler |
| collection | DOAJ |
| description | Introduction: Depression is an emotional disorder associated with morbidities and disabilities worldwide. The growing use of antidepressants is a concern for health managers because there are still unanswered questions on the effectiveness and safety of these medicines. Drug sales have increased in Brazil in recent years, but investigations on antidepressants sales are not available. We aimed to describe the trends in the antidepressant commerce in Brazil in a five-year period.Materials and Methods: We performed an ecological study on antidepressant sales in Brazil, from November 2014 to October 2019, using data from IQVIA™, a data provider of pharmaceutical sales. Antidepressants were coded by the Anatomical Therapeutic Chemical classification system, and sales were presented in defined daily doses (DDDs) and DDDs per 1,000 inhabitants per day (DIDs). The results were expressed in absolute quantities and growth rates.Results: The analyzed dataset contained 23 active substances in 780 products. The total sales of antidepressants increased from 23.3 DIDs in November 2014 to 38.3 DIDs in October 2019 (p = 0.002). Selective serotonin reuptake inhibitors were the most sold category of drugs (+5.7 million DDDs) in the period. ‘Other’ antidepressants presented the largest growth rate (104.7%). Individually, the most sold active substance was escitalopram (+1.8 million DDDs), and vortioxetine had the largest growth rate (336.2%). Tricyclic sales remained unchanged, and monoamine oxidase inhibitors had low and even decreasing sales (−9.5%).Discussion: The total sales of antidepressants increased in Brazil from November 2014 to October 2019. The higher sale volumes of selective serotonin reuptake inhibitors and higher growth rate of ‘other’ antidepressants, with low sale volume of tricyclics and a decrease of monoamine oxidase inhibitors, suggest the replacement of older drugs by newer ones following a global trend. Therapeutic advances and commercial promotion efforts on new products might explain these findings. |
| first_indexed | 2024-04-11T09:16:28Z |
| format | Article |
| id | doaj.art-dc22d7b3a22c4b6286d5d9a4c85b48bb |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T09:16:28Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-dc22d7b3a22c4b6286d5d9a4c85b48bb2022-12-22T04:32:20ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.893891893891Trends in Brazilian market of antidepressants: A five-year dataset analysisRogério Hoefler0Rogério Hoefler1Taís Freire Galvão2Inês Ribeiro-Vaz3Inês Ribeiro-Vaz4Marcus Tolentino Silva5Department of Community Medicine, Health Information and Decision, Faculty of Medicine, University of Porto, Porto, PortugalFederal Council of Pharmacy, Brasília, BrazilFaculty of Pharmaceutical Sciences, University of Campinas, Campinas, BrazilPorto Pharmacovigilance Centre, Faculty of Medicine, University of Porto, Porto, PortugalCenter for Health Technology and Services Research (CINTESIS), Faculty of Medicine, University of Porto, Porto, PortugalUniversity of Sorocaba, Sorocaba, BrazilIntroduction: Depression is an emotional disorder associated with morbidities and disabilities worldwide. The growing use of antidepressants is a concern for health managers because there are still unanswered questions on the effectiveness and safety of these medicines. Drug sales have increased in Brazil in recent years, but investigations on antidepressants sales are not available. We aimed to describe the trends in the antidepressant commerce in Brazil in a five-year period.Materials and Methods: We performed an ecological study on antidepressant sales in Brazil, from November 2014 to October 2019, using data from IQVIA™, a data provider of pharmaceutical sales. Antidepressants were coded by the Anatomical Therapeutic Chemical classification system, and sales were presented in defined daily doses (DDDs) and DDDs per 1,000 inhabitants per day (DIDs). The results were expressed in absolute quantities and growth rates.Results: The analyzed dataset contained 23 active substances in 780 products. The total sales of antidepressants increased from 23.3 DIDs in November 2014 to 38.3 DIDs in October 2019 (p = 0.002). Selective serotonin reuptake inhibitors were the most sold category of drugs (+5.7 million DDDs) in the period. ‘Other’ antidepressants presented the largest growth rate (104.7%). Individually, the most sold active substance was escitalopram (+1.8 million DDDs), and vortioxetine had the largest growth rate (336.2%). Tricyclic sales remained unchanged, and monoamine oxidase inhibitors had low and even decreasing sales (−9.5%).Discussion: The total sales of antidepressants increased in Brazil from November 2014 to October 2019. The higher sale volumes of selective serotonin reuptake inhibitors and higher growth rate of ‘other’ antidepressants, with low sale volume of tricyclics and a decrease of monoamine oxidase inhibitors, suggest the replacement of older drugs by newer ones following a global trend. Therapeutic advances and commercial promotion efforts on new products might explain these findings.https://www.frontiersin.org/articles/10.3389/fphar.2022.893891/fullantidepressive agentsdrug utilizationmarket researchcommerceBrazil |
| spellingShingle | Rogério Hoefler Rogério Hoefler Taís Freire Galvão Inês Ribeiro-Vaz Inês Ribeiro-Vaz Marcus Tolentino Silva Trends in Brazilian market of antidepressants: A five-year dataset analysis Frontiers in Pharmacology antidepressive agents drug utilization market research commerce Brazil |
| title | Trends in Brazilian market of antidepressants: A five-year dataset analysis |
| title_full | Trends in Brazilian market of antidepressants: A five-year dataset analysis |
| title_fullStr | Trends in Brazilian market of antidepressants: A five-year dataset analysis |
| title_full_unstemmed | Trends in Brazilian market of antidepressants: A five-year dataset analysis |
| title_short | Trends in Brazilian market of antidepressants: A five-year dataset analysis |
| title_sort | trends in brazilian market of antidepressants a five year dataset analysis |
| topic | antidepressive agents drug utilization market research commerce Brazil |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.893891/full |
| work_keys_str_mv | AT rogeriohoefler trendsinbrazilianmarketofantidepressantsafiveyeardatasetanalysis AT rogeriohoefler trendsinbrazilianmarketofantidepressantsafiveyeardatasetanalysis AT taisfreiregalvao trendsinbrazilianmarketofantidepressantsafiveyeardatasetanalysis AT inesribeirovaz trendsinbrazilianmarketofantidepressantsafiveyeardatasetanalysis AT inesribeirovaz trendsinbrazilianmarketofantidepressantsafiveyeardatasetanalysis AT marcustolentinosilva trendsinbrazilianmarketofantidepressantsafiveyeardatasetanalysis |